… assess the impact of long-acting bronchodilator therapy and associated exposure to inhaled
… to long-acting bronchodilators only and 3,510 to long-acting bronchodilators plus ICS. 1,372 …

… added a different long-acting bronchodilator thereby terminating study participation, a lower
… of a long-acting bronchodilator prior to the administrative end of the study (58% compared …

… This study aimed to characterize patients with chronic obstructive pulmonary disease (COPD)
newly prescribed a long-acting bronchodilator (LABD), and to assess changes in …

… -acting bronchodilators, we conducted a cohort study. Specifically, the study compared
the safety of the only approved long-acting … the single-ingredient long-acting β-agonists (LABAs) …

… Current COPD management guidelines advocate a stepwise approach using long acting
bronchodilators (including β agonists) and inhaled corticosteroids to reduce exacerbations and …

… years) in the present study for the ICS-containing and LABD cohorts, respectively (48.7
and 30.9) are lower than reported in the 3-year TORCH study of FP/salmeterol combination (84–…

… understanding of the comparative efficacy of long-acting bronchodilators in COPD, it is important
to … the two studies--most notably differences in study population, design, and outcomes. …

… studies in real-world settings have assessed the comparative safety of inhaled long-acting
bronchodilator … Therefore, we conducted a population-based retrospective cohort study to …

… Bronchodilator medications are central to the symptomatic … a short-acting bronchodilator,
whether it be a β 2 -agonist, an anticholinergic, or a combination of these two bronchodilators, …

… any study drug of interest (long-acting bronchodilators or ICS)… , and short-acting anticholinergic
drugs were frequently used. … with the ECLIPSE study (Citation32), in our cohort we found …